Intercure annual debt-to-equity ratio
2020
2021
2022
2023
2024
2025
Intercure Debt-to-Equity Ratio Growth & History (INCR)
Intercure's debt-to-equity ratio was 0.46 for fiscal 2025.
View full Intercure company overviewIntercure annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.46 | −0.07 | −13.16% |
| 2024 | 2024-12-31 | 0.53 | 0.10 | +23.87% |
| 2023 | 2023-12-31 | 0.43 | −0.08 | −15.46% |
| 2022 | 2022-12-31 | 0.51 | 0.27 | +112.31% |
| 2021 | 2021-12-31 | 0.24 | 0.22 | +1446.02% |
| 2020 | 2020-12-31 | 0.02 | — | — |
Intercure quarterly debt-to-equity ratio
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.46 | −0.07 | −13.16% |
| Q4 2024 | 2024-12-31 | 0.53 | 0.10 | +23.87% |
| Q4 2023 | 2023-12-31 | 0.43 | −0.08 | −15.46% |
| Q4 2022 | 2022-12-31 | 0.51 | 0.27 | +112.31% |
| Q4 2021 | 2021-12-31 | 0.24 | 0.22 | +1446.02% |
| Q4 2020 | 2020-12-31 | 0.02 | — | — |
Intercure debt-to-equity ratio trends
Over the last five fiscal years, Intercure's debt-to-equity ratio increased from 0.02 to 0.46, a change of 0.45. The latest reported quarter, Q4 2025, shows 0.46.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intercure source filings ↗Community posts
InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific defic ...